LCS Constructors, Inc. Moves Agendia Into Irvine ... and the Future

IRVINE, Calif., Aug. 24 /PRNewswire/ -- LCS Constructors, Inc. (LCS) recently completed a new state-of-the-art clinical genomic laboratory for Agendia, Inc. Formerly located in Huntington Beach, CA, the new laboratory will support Agendia's expansion in the U.S. marketplace, and increase their clinical research capabilities.

When Agendia decided to relocate their cancer research facility to Irvine, CA, they found a building previously outfitted with three laboratories and two cleanrooms. LCS modified the new space to accommodate Agendia's unique laboratory needs with the required electrical, plumbing, casework and some mechanical work. Some of the upgrades included a complete electrical labeling and the rework of several electrical branch circuits, new laboratory sinks, and one new emergency shower and eyewash combination.

Agendia, an innovative genomic cancer diagnostics company, uses its knowledge and expertise to facilitate breast cancer diagnosis, breast cancer prognosis and breast cancer treatment. Agendia's lead product, MammaPrint®, is a breast cancer test designed to determine a patient's risk of metastases providing a more personalized approach to breast cancer therapy. It is also the only FDA-cleared breast cancer recurrence test on the market.

The official opening of the laboratory took place on August 5, 2010 marked by a high profile ribbon cutting ceremony which was attended by a large group of California politicians and other VIPs, including the Mayor of Irvine, Sukhee Kang, as well as representatives of patient advocacy organizations and clinicians. David Skinner, Vice President of LCS, Tiffany Amber Farran, Manager of Business Development and Marketing with LCS, and Kevin Garrett, Electrical Project Manager with LCS also attended the ceremony.

Today the new facility consists of corporate offices and a 15,000 square foot high-tech genomic laboratory. LCS was proud to deliver Agendia's new facility, and more importantly, to play a vital role in providing a facility that assists in personalizing medicine for newly diagnosed breast cancer patients with cutting edge technology. The new facility will surely serve as a catalyst for Agendia's continued and very specialized cancer technology.  

SOURCE LCS Constructors, Inc.